BCR and B-cell chronic lymphocytic leukemia: A large number of CLL patients treated with BTK or PI3Kδ inhibitors (i.e. Ibrutinib and idelalisib), which primarily target BCR signaling, achieve durable responses, corroborating the relevance of BCR signaling in CLL pathogenesis [7].